Overview

Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer

Status:
Completed
Trial end date:
2001-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if topotecan is more effective given by infusion or by mouth. PURPOSE: Randomized phase III trial to compare the effectiveness of topotecan given by infusion with that of topotecan given by mouth in treating patients who have small cell lung cancer that has relapsed following previous therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Case Comprehensive Cancer Center
Collaborator:
Smith Kline Beecham
Treatments:
Topotecan